CClinicalTrials.gg
RecruitingNCT07219251EVLCUpdated Mar 3, 2026

Engagement of Veterans With Lung Cancer

An interventional study of Lay Health Worker (LHW) Planning and Usual Care Group in Lung Cancer (NSCLC), Lung Adenocarcinoma and Lung Cancer, Non-Small Cell, sponsored by Palo Alto Veterans Institute for Research. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Palo Alto Veterans Institute for Research · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This research study will help our understanding of whether additional support for Veterans with lung cancer can improve their quality of life.

Read the detailed description

This study aims to evaluate whether a lay health worker who provides education and support regarding goals of care and symptom management can improve health-related quality of life among Veterans with newly diagnosed lung cancer and those receiving treatment or who have completed treatment within 12 months as compared to usual care. We will also determine whether the intervention reduces acute care use and explore effects on anxiety and depression, patient activation, and goals of care communication. This knowledge is important as it will help to improve care for Veterans with lung cancer.

PRIMARY OBJECTIVES:

i.) Health-related quality of life

SECONDARY OBJECTIVES:

i.) acute care use ii.) patient activation iii.) anxiety and depression iv.) documentation of goals of care (GoC) v.) palliative care use vi.) hospice use

OUTLINE: The study will enroll and randomize 1:1 a total of 194 Veterans diagnosed with lung cancer (any stage).

Arm A: Participants randomized to the usual care group will receive usual care provided by their oncology clinical team.

Arm B: Participants randomized to the LHW group will receive usual care provided by their oncology clinical team and also receive weekly telephone calls with a trained lay health worker to assist with healthcare planning, symptom management, and discussions about care preferences and goals for 6 months.

All participants regardless of group randomization, will be required to complete surveys at the start of the study and at 3-month intervals for 12 months (i.e., at enrollment, 3 months, 6 months, 9 months, and 12 months).

02

Conditions studied

  • Lung Cancer (NSCLC)
  • Lung Adenocarcinoma
  • Lung Cancer, Non-Small Cell
  • Lung Carcinoma
  • Lung Cancer, Small Cell
  • Lung Adenocarcinoma With Bronchiolo-alveolar Feature

Keywords

  • lung
  • cancer
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Veteran patients with diagnosis of any stage of lung cancer;
  2. 18 years of age or older;
  3. English- or Spanish-speaking;
  4. can self-administer questionnaires in English or Spanish;
  5. valid telephone number;
  6. receiving oncology care at participating sites;
  7. currently newly diagnosed or receiving or having completed systemic anti-cancer therapy and/or radiation therapy within 12 months, defined as oral, injection, or intravenous therapy (chemotherapy, targeted therapy, or immunotherapy)

Exclusion criteria

Exclusion Criteria:

  1. no capacity to consent;
  2. actively receiving hospice care
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
194 participants (estimated)

Study arms

  • Active comparator
    Usual Care - Arm A

    Patients randomized to this group will receive usual care provided by their oncology(or primary) clinical team.

    Other: Usual Care Group

  • Experimental
    Intervention Lay Health Worker (LHW) - Arm B

    Participants randomized to this arm of the study will receive usual care with supplemental education and support provided by a lay health worker (LHW) to assist with healthcare planning, symptom management, and discussions about care preferences and goals.

    Behavioral: Lay Health Worker (LHW) Planning

Interventions

  • BehavioralLay Health Worker (LHW) Planning

    Patients randomized to the LHW group will receive usual care provided by their oncology (or primary) clinical team along with an initial 30-minute telephone call with the LHW from Palo Alto, followed by weekly 15-minute phone calls (or as needed) for 6months. These calls are designed to assist with healthcare planning, symptom management, and discussions about care preferences and goals.

  • OtherUsual Care Group

    Participants randomized to the usual care group will receive usual care provided by their oncology clinical team. These teams have been trained in symptom assessment, goals-of-care (GoC) discussions, and documentation of such clinical services. As part of usual care, participants may engage in symptom and GoC discussions at any time, initiated by either the patient or the clinician.

    Also known as: Usual Care

05

What researchers measure

Primary outcomes

  1. Health-Related Quality of Life

    Change in Health-related quality of life using the 36-item validated Functional Assessment of Cancer Therapeutics-Lung (FACT-L) survey.

    Time frame: At Baseline (time of enrollment), 3, 6, 9, and 12 months post-enrollment

Secondary outcomes

  1. Emergency Department Visits (Self-reported and Chart Review)

    Emergency Department use will be self-reported by each patient or abstracted by electronic medical record at 3, 6, 9 and 12 months after enrollment.

    Time frame: From baseline (time of enrollment) to 12 Months post-enrollment

  2. Hospitalization Visits (Self-reported and Chart Review)

    Hospital use for each patient will be self-reported by each patient or abstracted by electronic medical record at 3, 6, 9 and 12 months after enrollment.

    Time frame: From baseline (time of enrollment) to 12 months post-enrollment

  3. Patient Activation Measure (PAM-10).

    Change in patient activation using 10-item validated survey Patient Activation Measure (PAM-10) assessing patient activation in their health and health care .

    Time frame: At baseline (time of enrollment), 3, 6, 9 and 12 months post-enrollment

  4. Patient-reported anxiety and depression

    Patient-reported anxiety and depression using the validated Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety and Depression scales

    Time frame: At baseline, 3, 6, 9 and 12 months post-enrollment

  5. Documentation of goals of care discussions (Chart Review)

    Documentation of goals of care discussions will be abstracted by electronic medical record chart review for each patient at 3, 6, 9 and 12 months after enrollment.

    Time frame: At baseline, 3, 6, 9 and 12 months post-enrollment

  6. Palliative Care Use (Self-reported and Chart Review)

    Palliative care use will be self-reported by each patient or abstracted by electronic medical record at 3, 6, 9 and 12 months after patient enrollment.

    Time frame: From baseline (time of enrollment) to 12 months post-enrollment

  7. Hospice Care Use (Self-reported and Chart Review)

    Hospice care use will be self-reported by each patient or abstracted by electronic medical record at 3, 6, 9 and 12 months after patient enrollment.

    Time frame: From baseline (time of enrollment) to 12 months post-enrollment

06

Study locations

1 of 1 sites recruiting
  • Veterans Affairs Palo Alto Health Care System (VAPAHCS)
    Palo Alto, California 94304, United States
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07219251
Lead sponsor
Palo Alto Veterans Institute for Research
Collaborators
United States Department of Defense, US Department of Veterans Affairs
Responsible party
Manali Patel (Staff Oncologist and Investigator, VA Palo Alto Health Care System) — Principal investigator
First posted
Oct 21, 2025
Start date
Feb 27, 2026
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Mar 3, 2026

Study contacts

Manali I Patel, MD MPH MS
Contact
manalip@stanford.edu
6504935000
Madhuri Agrawal, MS
Contact
madhuri.agrawal@va.gov
650-304-7744

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion